Search results for "Roca"

showing 10 items of 1893 documents

CCDC 141172: Experimental Crystal Structure Determination

2001

Related Article: Young Lag Cho, D.M.Rudkevich, A.Shivanyuk, K.Rissanen, J.Rebek Junior|2000|Chem.-Eur.J.|6|3788|doi:10.1002/1521-3765(20001016)6:20<3788::AID-CHEM3788>3.0.CO;2-Y

25262728-tetrakis((N-n-Butylcarbamoyl)methoxy)-5111723-tetra-nitrocalix(4)arene acetonitrile solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Realización de un electrocardiograma

2010

Procedimiento a realizar para obtener un registro electrocardiográfico. Preparación del paciente y del electrocardiógrafo.

3213.11 Ciències MédiquesExploración clínicofuncionalcardiopatíaselectrocardiografía básicaFisioterapia3213.11- Farmacia Medicina
researchProduct

A subset of flavaglines inhibits KRAS nanoclustering and activation.

2020

The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these int…

:Bioengineering [Engineering]Neuroblastoma RAS viral oncogene homologGene isoformLung NeoplasmsGTP'[SDV]Life Sciences [q-bio]AucunBiology: Biochemistry biophysics & molecular biology [F05] [Life sciences]medicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRocaglamideCarcinoma Non-Small-Cell LungmedicineKRASHumansdrug therapy;geneticsgeneticsHRASProhibitin: Biochimie biophysique & biologie moléculaire [F05] [Sciences du vivant]neoplasmsComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesOncogeneLipid nanoclusterOncogenesCell Biologydigestive system diseases3. Good healthrespiratory tract diseasesPhospholipidchemistry030220 oncology & carcinogenesisMutationCancer researchKRASFlavaglineRocaglamideProhibitinSignal Transduction
researchProduct

Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales

2014

“Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales” es la primera parte de un trabajo de documentación para un capítulo de “La democracia en la Comunidad Valenciana. Partidos, elites políticas, elecciones y programas políticos”. “Mujer, poder político y democracia paritaria”. Se recoge el papel de la mujer en la vida política de la Comunidad Valenciana en la democracia actual, desde 1977. Es documentación sin elaborar, pero que aporta datos de la presencia de la mujer en las instituciones, partidos y sindicatos. Cuando este completa será una parte de la investigación referida, y de la que ya hay dos publicacion…

:CIENCIA POLÍTICA [UNESCO]UNESCO::HISTORIAUNESCO::CIENCIA POLÍTICA:HISTORIA [UNESCO]Dolores Ibarruri Pasionaria. Josefina López Sanmartín PCE. Ciprià Císcar Casabán. Pilar Brabo Castells. Palmira Pla Pechoviento. Adela Pla Pastor. democracia paritaria. Asunción Cruañes Molina. Carmen Alborch Bataller. Maria A. Armengol Criado. Clementina Rodenas Villena. Rita Barberá Nolla. Irma Simón Calvo. Teresa Sempere Jaén. Ofelia Soler Nomdedeu. María C. Díaz Villanueva. María Carmen Pardo Raga. Eva María Amador Guillén. Presentación Urán González. María Isabel Díez de la Lastra Barbadillo. Elena Irene Martín Crevillén. María Enriqueta Seller Roca de Togores. María Carmen Pardo Raga. Eva María Amador Guillén. María J. Mora Devis. Olga Mulet Torres. Margarita Pin Arboledas. Juana Serna Masiá. Leire Pajín Iraola. Rosa M. Peris Cervera. Amparo Ferrando. Carmen Arjona. María I. España Moya. Federica Montseny Mañé. Matilde Fernández Sanz. Rosa Conde Gutiérrez del Álamo. María de los Ángeles Amador Millán. Cristina Alberdi Alonso. Margarita Mariscal de Gante Mirón. Esperanza Aguirre Gil de Biedma. Loyola de Palacio del Valle-Lersundi. Isabel Tocino Biscarolasaga. Pilar del Castillo Vera. Celia Villalobos Talero. Anna María Birulés Beltrán Ana Pastor. Ana de Palacio del Valle-Lersundi. Elvira Rodríguez Herrero. Julia García-Valdecasas. Ana Mª Castellanos Vilar. Elena Mª Martín Yánez. Paloma Gómez Osorio. Concepción Pérez Morales. Francisca Benabent Fuentes. Carmen Monzó Juan. Rosa Mª Morte Julián. Gloria Marcos Martí. Lourdes Alonso Belza. Pilar Pedraza. María García-Lliberos Sánchez-Robles. Blanca Blanquer. Dolors Giner Duran. Teresa Fluvía Rodríguez. Trinidad Simó. Emilia Noguera. Hortensia Moriones Almaraz. Carolina García Mahiques. Hortensia Moriones Almaraz. Juana Serna Maciá. Lourdes Alonso Belza. Inmaculada Rodríguez-Piñero Fdez. Carmen Macián Armengod. Carmen Moya García. María José López Rodenas. María Juan Millet. Alicia de Miguel García. Ana Encabo Balbín. Ana Michavila Nuñez. Isabel Villalonga Campos. Carmen Dolz Adell. Eva Maria Amador Guillen. Alida C. Mas Taberner. Dora Ibars Sancho. Amparo Koninckx Frasquet. Blanca Martínez de Vallejo Fuster. Consuelo Císcar Casabán. Auxiliadora Hernández Miñana. Silvia Caballer Almela. Gemma Amor Pérez. Emma Iranzo Martín. Cristina Serrano Mateo. Cristina Santamarina Ciurana
researchProduct

Berrocal Lanzarot, A. L. : Estudio jurídico-crítico sobre la ley orgánica 3/2018, de 5 de diciembre, de protección de datos personales y garantía de …

2021

:CIENCIAS JURÍDICAS [UNESCO]2070-8157 22082 Revista Boliviana de Derecho 565487 2021 31 7730077 Berrocal LanzarotUNESCO::CIENCIAS JURÍDICASA. L. Estudio jurídico-crítico sobre la ley orgánica 3/2018David 758 763de 5 de diciembrede protección de datos personales y garantía de los derechos digitales López Jiménez
researchProduct

Síntesis y caracterización de materiales basados en los sistemas Pr-ZrO2 y Pr-ZrSiO4. Propiedades y aplicaciones.

2014

En el presente trabajo se estudian las disoluciones sólidas Pr-ZrSiO4 y Pr-ZrO2. La disolución sólida Pr-ZrSiO4 despierta un gran interés a nivel industrial por su estabilidad química y su aplicación como pigmento cerámico. Este pigmento presenta una coloración amarilla debido al catión praseodimio y ha sido ampliamente estudiado para mejorar su producción industrial. Sin embargo, en este trabajo se realiza un estudio de la disolución sólida Pr-ZrSiO4 para profundizar en sus características estructurales y microestructurales. Así se han tratado diferentes aspectos tales como el intervalo composicional de la disolución sólida, la ocupación del catión praseodimio en la estructura de circón y …

:CIENCIAS TECNOLÓGICAS [UNESCO]procesos electrocataliticosUNESCO::QUÍMICAUNESCO::CIENCIAS TECNOLÓGICAS:QUÍMICA [UNESCO]PraseodimiocircóncirconaDisoluciones sólidas
researchProduct

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations

2007

Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment o…

:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Veterinary medicine:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Streptomycin [Medical Subject Headings]:Phenomena and Processes::Microbiological Phenomena::Drug Resistance Microbial [Medical Subject Headings]DiseaseGlobal Health:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Health Care::Population Characteristics::Health::World Health [Medical Subject Headings]Terminología como AsuntoBrucellosi:Organisms::Eukaryota::Animals [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::International Agencies::United Nations::World Health Organization [Medical Subject Headings]Policy ForumMedicine in Developing CountriesGentamicinasDrug Resistance MicrobialBrucelosisAdhesión a DirectrizGeneral MedicineHumanosDrug CombinationsAntibacterianosDoxycyclineStreptomycinEstreptomicinaMedicine:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds with 4 or More Rings::Rifamycins::Rifampin [Medical Subject Headings]Drug Therapy CombinationGuideline AdherenceRifampinFluoroquinolonesSalud Mundialmedicine.medical_specialtyEfficacyResultado del TratamientoInvestigación BiomédicaRecurrenciaTherapeuticsWorld Health OrganizationMicrobiologyAntibiotic resistanceTerminology as Topic:Disciplines and Occupations::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings]HumansMedical journalIntensive care medicineDeveloping Countries:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Trimethoprim::Trimethoprim-Sulfamethoxazole Combination [Medical Subject Headings]medicine.diseaseCotrimoxazoleAnimalesQuimioterapia:Humanities::Humanities::History::History Modern 1601-::History 21st Century [Medical Subject Headings]GentamicinsBrucel·losiBiomedical ResearchCommunicable diseases:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 2-Ring::Quinolines::Quinolones::Fluoroquinolones [Medical Subject Headings]Human diseaseRecurrence:Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings]:Information Science::Information Science::Communication::Language::Linguistics::Terminology as Topic [Medical Subject Headings]biologyIraqi patientsRMetaanalysis:Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Brucellosis [Medical Subject Headings]Historia del Siglo XXIAnti-Bacterial AgentsCombinación Trimetoprim-SulfametoxazolTreatment OutcomeInfectious Diseases:Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research [Medical Subject Headings]:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Tetracyclines::Doxycycline [Medical Subject Headings]Fluoroquinolonas:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [Medical Subject Headings]:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins [Medical Subject Headings]Países en Desarrollo:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy Combination [Medical Subject Headings]BrucellaHistory 21st CenturyBrucellosisWorld healthTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimals:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]Resistencia a Medicamentosbusiness.industryOrganización Mundial de la SaludBrucellosisMalalties infecciosesTerapèuticabiology.organism_classificationCombinación de MedicamentosDoxiciclinaTherapybusinessBrucella melitensisPLoS Medicine
researchProduct

El paisatge vegetal de la Marina, a partir dels carbons prehistòrics

1997

Badal Garcia, Ernestina - Ernestina.Badal@uv.es

:GEOGRAFÍA [UNESCO]paisatge vegetal ; cova de les cendres ; cova foradada ; cova del bolumini ; tossal de la roca ; clímax forestalpaisatge vegetalUNESCO::HISTORIA::Historia por épocas::Prehistoriacova foradadatossal de la rocacova de les cendresclímax forestalcova del bolumini:HISTORIA::Historia por épocas::Prehistoria [UNESCO]UNESCO::GEOGRAFÍAAguaits
researchProduct

Vaccinium macrocarpon (Cranberry)-Based Dietary Supplements: Variation in Mass Uniformity, Proanthocyanidin Dosage and Anthocyanin Profile Demonstrat…

2020

Vaccinium macrocarpon (syn. American Cranberry) is employed in dietary supplements (DS) with the aim to improve urinary tract well-being. This property is linked to the antiadhesion-activity of proanthocyanidins (PACs) against uropathogenic-bacteria. However, the current European legislation has been criticized for being weak and ineffective. Indeed, recent scientific works report mislabeled, contaminated, and adulterated supplements containing dangerous or unknown compounds, or sold at toxic doses. In this work, we analysed 24 DS that claim to contain cranberry, and to have a specific dosage of PACs. Our tests included the control of the good manufacturing practice according to the Europea…

<i>Vaccinium macrocarpon</i>Anthocyanin0301 basic medicineSettore CHIM/10 - Chimica Degli Alimentilcsh:TX341-641Articlechemical fingerprintinglaw.inventionAnthocyaninsdietary supplements03 medical and health scienceschemistry.chemical_compoundBL-DMAC0404 agricultural biotechnologyfoodlawSettore BIO/10 - BiochimicaAmerican cranberry; Anthocyanins; BL-DMAC; Chemical fingerprinting; Dietary supplements; HPLC-UV/Vis; Orbitrap; Proanthocyanidins; Vaccinium macrocarponEuropean marketVaccinium macrocarponMedicineProanthocyanidinsFood scienceAmerican cranberry030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryHPLC-UV/Vis04 agricultural and veterinary sciencesOrbitrap040401 food scienceAmerican cranberryfood.foodVaccinium macrocarponProanthocyanidinchemistrydietary supplementAnthocyaninProanthocyanidinPharmacopoeiaHPLC-UV/Vibusinesslcsh:Nutrition. Foods and food supplyChemical fingerprintingFood ScienceNutrients
researchProduct